{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:13:35Z","timestamp":1783728815378,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jacadv.2026.102840","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T19:24:38Z","timestamp":1781724278000},"page":"102840","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["Beta-Blocker Discontinuation After Myocardial Infarction"],"prefix":"10.1016","volume":"5","author":[{"given":"Wade","family":"Thompson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Alaeiilkhchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raha","family":"Eskandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanrong Maggie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arden R.","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas M.","family":"Salzwedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7474-3737","authenticated-orcid":false,"given":"Parag","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7200","key":"10.1016\/j.jacadv.2026.102840_bib1","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1136\/bmj.318.7200.1730","article-title":"Beta Blockade after myocardial infarction: systematic review and meta regression analysis","volume":"318","author":"Freemantle","year":"1999","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.jacadv.2026.102840_bib2","first-page":"1577","article-title":"Beta-blocker therapy after myocardial infarction: is there an expiry date?","volume":"36","author":"Qamar","year":"2020","journal-title":"Can J Cardiol"},{"issue":"3","key":"10.1016\/j.jacadv.2026.102840_bib3","article-title":"Beta-blocker therapy after myocardial infarction","volume":"4","author":"Cataldo Miranda","year":"2025","journal-title":"JACC: Adv"},{"issue":"15","key":"10.1016\/j.jacadv.2026.102840_bib4","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1056\/NEJMoa2401479","article-title":"Beta-blockers after myocardial infarction and preserved ejection fraction","volume":"390","author":"Yndigegn","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.102840_bib5","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2504735","article-title":"Beta-blockers after myocardial infarction without reduced ejection fraction","author":"Ibanez","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.102840_bib6","article-title":"Beta-blockers after myocardial infarction with normal ejection fraction","author":"Kristensen","year":"2025","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.jacadv.2026.102840_bib7","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1016\/j.jacc.2019.03.467","article-title":"Deprescribing in older adults with cardiovascular disease","volume":"73","author":"Krishnaswami","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.102840_bib8","author":"Higgins"},{"key":"10.1016\/j.jacadv.2026.102840_bib9","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.jacadv.2026.102840_bib10","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/eurjpc\/zwae298","article-title":"Beta-blockers for secondary prevention following myocardial infarction in patients without reduced ejection fraction or heart failure: an updated meta-analysis","volume":"32","author":"Chi","year":"2025","journal-title":"Eur J Prev Cardiol"},{"issue":"8","key":"10.1016\/j.jacadv.2026.102840_bib12","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/eurjpc\/zwae346","article-title":"Safety of beta-blocker discontinuation after acute coronary syndromes with preserved or mildly reduced left ventricular ejection fraction: a target trial emulation from a real-world cohort","volume":"32","author":"Johner","year":"2025","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"10.1016\/j.jacadv.2026.102840_bib13","article-title":"Continuation vs withdrawal of beta-blockers and outcomes after myocardial infarction with preserved left ventricular function","volume":"4","author":"Chiu","year":"2025","journal-title":"JACC: Adv"},{"issue":"14","key":"10.1016\/j.jacadv.2026.102840_bib14","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa2404204","article-title":"Beta-blocker interruption or continuation after myocardial infarction","volume":"391","author":"Silvain","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jacadv.2026.102840_bib15","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/clc.23807","article-title":"The duration of beta-blocker therapy and outcomes in patients without heart failure or left ventricular systolic dysfunction after acute myocardial infarction: a multicenter prospective cohort study","volume":"45","author":"Wen","year":"2022","journal-title":"Clin Cardiol"},{"issue":"37","key":"10.1016\/j.jacadv.2026.102840_bib16","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000035187","article-title":"Sustained beneficial effect of \u03b2-blockers on clinical outcomes after discontinuation in patients with ST elevation myocardial infarction","volume":"102","author":"Park","year":"2023","journal-title":"Medicine"},{"key":"10.1016\/j.jacadv.2026.102840_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.i4801","article-title":"\u03b2 blockers and mortality after myocardial infarction in patients without heart failure: Multicentre prospective cohort study","author":"Puymirat","year":"2016","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.jacadv.2026.102840_bib18","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/ehjcvp\/pvad046","article-title":"The effect of discontinuing beta-blockers after different treatment durations following acute myocardial infarction in optimally treated, stable patients without heart failure: a Danish, nationwide cohort study","volume":"9","author":"Halili","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"17","key":"10.1016\/j.jacadv.2026.102840_bib19","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1093\/eurheartj\/ehn346","article-title":"Discontinuation of statin therapy following an acute myocardial infarction: a population-based study","volume":"29","author":"Daskalopoulou","year":"2008","journal-title":"Eur Heart J"},{"issue":"17","key":"10.1016\/j.jacadv.2026.102840_bib20","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1001\/archinte.166.17.1842","article-title":"Impact of medication therapy discontinuation on mortality after myocardial infarction","volume":"166","author":"Ho","year":"2006","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.1016\/j.jacadv.2026.102840_bib21","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.117.004356","article-title":"Clinical events after discontinuation of \u03b2-Blockers in patients without heart failure optimally treated after acute myocardial infarction","volume":"11","author":"Neumann","year":"2018","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"9","key":"10.1016\/j.jacadv.2026.102840_bib22","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the management of patients with chronic coronary disease: a report of the American heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"82","author":"Virani","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.jacadv.2026.102840_bib23","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1368-5031.2005.00520.x","article-title":"Withdrawal syndrome following cessation of antihypertensive drug therapy","volume":"59","author":"Karachalios","year":"2005","journal-title":"Int J Clin Pract"},{"issue":"6","key":"10.1016\/j.jacadv.2026.102840_bib24","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1136\/hrt.45.6.637","article-title":"Adrenergic hypersensitivity after beta-blocker withdrawal","volume":"45","author":"Ross","year":"1981","journal-title":"Heart"},{"issue":"2","key":"10.1016\/j.jacadv.2026.102840_bib25","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/0002-8703(82)90142-9","article-title":"Comparison of withdrawal phenomena after propranolol, metoprolol, and pindolol","volume":"104","author":"Rangno","year":"1982","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.jacadv.2026.102840_bib26","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJMc2414217","volume":"392","year":"2025","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jacadv.2026.102840_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-086971","article-title":"Discontinuation of \u03b2-blocker therapy in stabilised patients after acute myocardial infarction (SMART-DECISION): rationale and design of the randomised controlled trial","volume":"14","author":"Choi","year":"2024","journal-title":"BMJ Open"},{"issue":"23","key":"10.1016\/j.jacadv.2026.102840_bib28","doi-asserted-by":"crossref","first-page":"e1434","DOI":"10.4244\/EIJ-D-25-00826","article-title":"Effect of beta blocker withholding or withdrawal after myocardial infarction without reduced ejection fraction on ischaemic events: a post hoc analysis from the REBOOT trial","volume":"21","author":"Rossello","year":"2025","journal-title":"EuroIntervention"},{"issue":"12","key":"10.1016\/j.jacadv.2026.102840_bib29","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1080\/14740338.2018.1546841","article-title":"An update on the clinical consequences of polypharmacy in older adults: a narrative review","volume":"17","author":"Wastesson","year":"2018","journal-title":"Expert Opin Drug Saf"},{"issue":"13","key":"10.1016\/j.jacadv.2026.102840_bib30","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/archinte.164.13.1389","article-title":"Adverse effects of \u03b2-Blocker therapy for patients with heart failure","volume":"164","author":"Ko","year":"2004","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1016\/j.jacadv.2026.102840_bib31","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1001\/jamainternmed.2016.7701","article-title":"Association of \u03b2-Blockers with functional outcomes, death, and rehospitalization in older nursing home residents after acute myocardial infarction","volume":"177","author":"Steinman","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"3","key":"10.1016\/j.jacadv.2026.102840_bib32","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jacc.2022.08.754","article-title":"2022 ACC expert consensus decision pathway for integrating atherosclerotic cardiovascular disease and multimorbidity treatment: a framework for pragmatic, patient-centered care","volume":"81","author":"Birtcher","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.jacadv.2026.102840_bib33","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1111\/jgs.19157","article-title":"Many studies, but little certainty about the effects of statin discontinuation on outcomes","volume":"72","author":"Odden","year":"2024","journal-title":"J Am Geriatr Soc"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26002619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26002619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T23:23:16Z","timestamp":1783725796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X26002619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2772963X26002619"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.102840","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beta-Blocker Discontinuation After Myocardial Infarction","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.102840","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"102840"}}